202 related articles for article (PubMed ID: 15522303)
21. 3D-QSAR CoMFA/CoMSIA studies on Urokinase plasminogen activator (uPA) inhibitors: a strategic design in novel anticancer agents.
Bhongade BA; Gadad AK
Bioorg Med Chem; 2004 May; 12(10):2797-805. PubMed ID: 15110861
[TBL] [Abstract][Full Text] [Related]
22. Urokinase-type plasminogen activator.
Crippa MP
Int J Biochem Cell Biol; 2007; 39(4):690-4. PubMed ID: 17118695
[TBL] [Abstract][Full Text] [Related]
23. Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-sulfonamidoisoquinolinyl)guanidines.
Fish PV; Barber CG; Brown DG; Butt R; Collis MG; Dickinson RP; Henry BT; Horne VA; Huggins JP; King E; O'Gara M; McCleverty D; McIntosh F; Phillips C; Webster R
J Med Chem; 2007 May; 50(10):2341-51. PubMed ID: 17447747
[TBL] [Abstract][Full Text] [Related]
24. Development of irreversible diphenyl phosphonate inhibitors for urokinase plasminogen activator.
Joossens J; Van der Veken P; Lambeir AM; Augustyns K; Haemers A
J Med Chem; 2004 May; 47(10):2411-3. PubMed ID: 15115382
[TBL] [Abstract][Full Text] [Related]
25. Structural basis for the highly selective inhibition of MMP-13.
Engel CK; Pirard B; Schimanski S; Kirsch R; Habermann J; Klingler O; Schlotte V; Weithmann KU; Wendt KU
Chem Biol; 2005 Feb; 12(2):181-9. PubMed ID: 15734645
[TBL] [Abstract][Full Text] [Related]
26. Novel inhibitor for prolyl tripeptidyl aminopeptidase from Porphyromonas gingivalis and details of substrate-recognition mechanism.
Xu Y; Nakajima Y; Ito K; Zheng H; Oyama H; Heiser U; Hoffmann T; Gärtner UT; Demuth HU; Yoshimoto T
J Mol Biol; 2008 Jan; 375(3):708-19. PubMed ID: 18042490
[TBL] [Abstract][Full Text] [Related]
27. (4-aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase.
Sperl S; Jacob U; Arroyo de Prada N; Stürzebecher J; Wilhelm OG; Bode W; Magdolen V; Huber R; Moroder L
Proc Natl Acad Sci U S A; 2000 May; 97(10):5113-8. PubMed ID: 10805774
[TBL] [Abstract][Full Text] [Related]
28. Development of serine protease inhibitors displaying a multicentered short (<2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasminogen activator and factor Xa.
Verner E; Katz BA; Spencer JR; Allen D; Hataye J; Hruzewicz W; Hui HC; Kolesnikov A; Li Y; Luong C; Martelli A; Radika K; Rai R; She M; Shrader W; Sprengeler PA; Trapp S; Wang J; Young WB; Mackman RL
J Med Chem; 2001 Aug; 44(17):2753-71. PubMed ID: 11495587
[TBL] [Abstract][Full Text] [Related]
29. X-ray structures of five renin inhibitors bound to saccharopepsin: exploration of active-site specificity.
Cronin NB; Badasso MO; J Tickle I; Dreyer T; Hoover DJ; Rosati RL; Humblet CC; Lunney EA; Cooper JB
J Mol Biol; 2000 Nov; 303(5):745-60. PubMed ID: 11061973
[TBL] [Abstract][Full Text] [Related]
30. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
Njoroge FG; Chen KX; Shih NY; Piwinski JJ
Acc Chem Res; 2008 Jan; 41(1):50-9. PubMed ID: 18193821
[TBL] [Abstract][Full Text] [Related]
31. Inhibitors of the protease domain of urokinase-type plasminogen activator.
Rockway TW; Nienaber V; Giranda VL
Curr Pharm Des; 2002; 8(28):2541-58. PubMed ID: 12369939
[TBL] [Abstract][Full Text] [Related]
32. Structural and biochemical studies of inhibitor binding to human cytomegalovirus protease.
Khayat R; Batra R; Qian C; Halmos T; Bailey M; Tong L
Biochemistry; 2003 Feb; 42(4):885-91. PubMed ID: 12549906
[TBL] [Abstract][Full Text] [Related]
33. Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator.
Frederickson M; Callaghan O; Chessari G; Congreve M; Cowan SR; Matthews JE; McMenamin R; Smith DM; Vinković M; Wallis NG
J Med Chem; 2008 Jan; 51(2):183-6. PubMed ID: 18163548
[TBL] [Abstract][Full Text] [Related]
34. Ab initio molecular orbital calculations on specific interactions between urokinase-type plasminogen activator and its receptor.
Nagase K; Kobayashi H; Yoshikawa E; Kurita N
J Mol Graph Model; 2009 Aug; 28(1):46-53. PubMed ID: 19403319
[TBL] [Abstract][Full Text] [Related]
35. Think twice: understanding the high potency of bis(phenyl)methane inhibitors of thrombin.
Baum B; Muley L; Heine A; Smolinski M; Hangauer D; Klebe G
J Mol Biol; 2009 Aug; 391(3):552-64. PubMed ID: 19520086
[TBL] [Abstract][Full Text] [Related]
36. Crystals of urokinase type plasminogen activator complexes reveal the binding mode of peptidomimetic inhibitors.
Zeslawska E; Jacob U; Schweinitz A; Coombs G; Bode W; Madison E
J Mol Biol; 2003 Apr; 328(1):109-18. PubMed ID: 12684001
[TBL] [Abstract][Full Text] [Related]
37. 2-(2-Hydroxy-3-alkoxyphenyl)-1H-benzimidazole-5-carboxamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors.
Mackman RL; Hui HC; Breitenbucher JG; Katz BA; Luong C; Martelli A; McGee D; Radika K; Sendzik M; Spencer JR; Sprengeler PA; Tario J; Verner E; Wang J
Bioorg Med Chem Lett; 2002 Aug; 12(15):2019-22. PubMed ID: 12113832
[TBL] [Abstract][Full Text] [Related]
38. Ecotin: a serine protease inhibitor with two distinct and interacting binding sites.
Yang SQ; Wang CI; Gillmor SA; Fletterick RJ; Craik CS
J Mol Biol; 1998 Jun; 279(4):945-57. PubMed ID: 9642073
[TBL] [Abstract][Full Text] [Related]
39. Calpain inhibition by alpha-ketoamide and cyclic hemiacetal inhibitors revealed by X-ray crystallography.
Cuerrier D; Moldoveanu T; Inoue J; Davies PL; Campbell RL
Biochemistry; 2006 Jun; 45(24):7446-52. PubMed ID: 16768440
[TBL] [Abstract][Full Text] [Related]
40. Bicyclic peptide inhibitor of urokinase-type plasminogen activator: mode of action.
Roodbeen R; Paaske B; Jiang L; Jensen JK; Christensen A; Nielsen JT; Huang M; Mulder FA; Nielsen NC; Andreasen PA; Jensen KJ
Chembiochem; 2013 Nov; 14(16):2179-88. PubMed ID: 24115455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]